|Day's Range||1.64 - 1.65|
|52 Week Range||0.95 - 1.75|
|PE Ratio (TTM)||-15.14|
|Earnings Date||May 12, 2017 - May 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1.65|
TORONTO and AMSTERDAM, The Netherlands, July 17, 2017 /PRNewswire/ - Norgine B.V. ("Norgine") and Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) ("Merus" or the "Company") are pleased to announce the closing of the plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). Norgine and Merus previously announced the signing of the arrangement agreement in respect of the Arrangement in a press release issued on May 11, 2017 and the issuance of the final order of the Supreme Court of British Columbia in respect of the Arrangement in a press release issued on July 12, 2017.
Norgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma market
TORONTO, July 12, 2017 /PRNewswire/ - Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) ("Merus" or the "Company") announced today that the Supreme Court of British Columbia has issued a final order approving the proposed transaction pursuant to which Norgine B.V. agreed to acquire all of the issued and outstanding common shares of Merus by way of a plan of arrangement (the "Arrangement"). Merus is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets.